Zayas Caridad, Bracho Gustavo, Lastre Miriam, González Domingo, Gil Danay, Acevedo Reinaldo, del Campo Judith, Taboada Carlos, Solís Rosa L, Barberá Ramón, Pérez Oliver
Immunology Department, Finlay Institute, P.O. Box 16017, Havana, Cuba.
Vaccine. 2006 Apr 12;24 Suppl 2:S2-94-5. doi: 10.1016/j.vaccine.2005.01.139.
Cochleate are highly stable structures with promising immunological features. Cochleate structures are usually obtaining from commercial lipids. Proteoliposome derived Cochleate are derived from an outer membrane vesicles of Neisseria meningitidis B. Previously, we obtained Cochleates using dialysis procedures. In order to increase the production process, we used a crossflow system (CFS) that allows easy scale up to obtain large batches in an aseptic environment. The raw material and solutions used in the production process are already approved for human application. This work demonstrates that CFS is very efficient process to obtain Cochleate structures with a yield of more than 80% and the immunogenicity comparable to that obtained by dialysis membrane.
